Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: AstraZeneca UK Ltd., 600 Capability Green, Luton, LU1 3LU, UK.
Alvesco 80 Inhaler.
| Pharmaceutical Form |
|---|
|
Pressurised inhalation, solution. Clear and colourless. |
1 actuation (delivered dose from the mouthpiece) contains 80 micrograms of ciclesonide.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Ciclesonide |
Ciclesonide exhibits low binding affinity to the glucocorticoid-receptor. Once orally inhaled, ciclesonide is enzymatically converted in the lungs to the principal metabolite (C21-des-methylpropionyl-ciclesonide) which has a pronounced anti-inflammatory activity and is thus considered as the active metabolite. |
| List of Excipients |
|---|
|
Norflurane (HFA-134a) |
The inhaler comprises a pressurised container made from aluminium and is sealed with a metering valve, mouthpiece, and cap.
30 metered actuations
60 metered actuations
120 metered actuations
Not all pack sizes may be marketed.
AstraZeneca UK Ltd., 600 Capability Green, Luton, LU1 3LU, UK.
PL 17901/0297
16 April 2004 / 24 February 2014
| Drug | Countries | |
|---|---|---|
| ALVESCO | Austria, Australia, Brazil, Canada, Cyprus, Germany, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
